DrugPatentWatch has been ranked the “Best Biopharmaceuticals Commercial Business Intelligence Platform” by Global Health & Pharma News This award is dedicated to honoring the innovation, determination and outstanding levels of…
Posts published in “Update”
Before the passage of the Biologic Patent Transparency Act DrugPatentWatch’s biologic patent data was cited as a reason why the law should not be passed. Thankfully, the Act advanced, and…
This is my talk from the 14th Annual Portfolio Planning and Partnership for Generic Conference. I discuss: Identifying generic entry opportunities at the earliest stages Discovering opportunities that avoid litigation…
I’ll be leading a workshop on generic portfolio management, and also giving a talk, at the 14th annual Marcus Evans event on Portfolio Planning and Partnerships for Generics. The event…
I’ll be leading a workshop on generic portfolio management, and also giving a talk, at the 14th annual Marcus Evans event on Portfolio Planning and Partnerships for Generics. The event…
Come join me and Wendi Lau from Abbvie as we participate in an interactive roundtable discussion on pharmaceutical portfolio management. We’ll be sharing our expertise and best practices for strategic…
New DrugPatentWatch module connects excipients and drug patents In response to user requests, DrugPatentWatch has added a new database of excipients (inactive ingredients) in drugs, and integrated it with our…
Are you tired of having to navigate complicated contracts to access the information you need? Let DrugPatentWatch free you from weeks of negotiating complex contracts and let you focus on…
DrugPatentWatch was featured in a recent article by Inc. Magazine. In their coverage of Mark Cuban’s new pharma company, they cited our published interview where Mark Cuban Sounds off on Drug Prices.…
Mark Schultz and Jaci McDole recently used DrugPatentWatch to complete a report on recent trends in the latest editions of the world health organization essential medicines list. Some of their key…
